Analyzing Saturna Capital Corp's Q3 and Q4 2022 13F Holdings Data to Identify Significant Changes

Saturna Capital Corp is an investment company that specializes in global investments across various sectors. The company's Q3 and Q4 2022 13F holdings data provides an insight into the company's investment strategy, especially with regards to the changes in the company's positions. In this blog post, we will analyze Saturna Capital Corp's Q3 and Q4 2022 13F holdings data to identify significant changes and provide insights into the company's investment strategy.

Before we begin our analysis, let's briefly explain what a 13F filing is. A 13F filing is a quarterly report filed by institutional investment managers with the US Securities and Exchange Commission (SEC). The report discloses the investment manager's holdings of publicly traded securities with a value of over $100 million as of the end of the quarter.

The 13F holdings data of Saturna Capital Corp for Q3 and Q4 2022 has been summarized in the CSV above. The data includes the issuer name, option type, the number of shares held in Q3 and Q4 2022, the value of the holdings in USD in Q3 and Q4 2022, and the percentage change in the holdings.

Upon analyzing the data, we can identify several significant changes in Saturna Capital Corp's holdings between Q3 and Q4 2022. Let's take a closer look at a few changes.

One noteworthy change is the increase in the value of the company's holdings of Eli Lilly (LLY) by 13% from $263,731,000 in Q3 to $298,138,000 in Q4. Another notable change is the decrease in the value of the company's holdings of Apple (AAPL) by 6.9% from $311,860,000 in Q3 to $290,211,000 in Q4.

The next change worth noting is the 31.5% increase in the value of Saturna Capital Corp's holdings of ASML Holding NY (ASML) from $130,687,000 in Q3 to $171,847,000 in Q4. Similarly, the company's holdings of Novo Nordisk ADS (NVO) increased by 35.5% from $106,761,000 in Q3 to $144,632,000 in Q4.

We can also observe changes in the company's holdings in a few other sectors. For instance, the company's position in the healthcare sector has increased with new positions in Bristol-Myers Squibb (BMY) and AbbVie (ABBV). On the other hand, the company reduced its position in Merck & Co (MRK) in Q4.

In the technology sector, we can observe a significant 21.7% increase in the value of the company's holdings of Adobe (ADBE), from $94,115,000 in Q3 to $114,528,000 in Q4. Furthermore, the company increased its position in NVIDIA (NVDA) in Q4.

Overall, the changes in the company's holdings data between Q3 and Q4 2022 suggest that Saturna Capital Corp has focused more on the healthcare and technology sectors. The company increased its holdings in some companies while reducing its position in others. These changes in holdings may reflect the company's investment strategy, which may have evolved to account for market trends and developments.

In conclusion, analyzing Saturna Capital Corp's Q3 and Q4 2022 13F holdings data provides us with useful insights into the company's investment strategy. While the full investment strategy of the company remains undisclosed, analyzing the quarterly 13F holdings data can give indications about changes in the company's priorities and investment strategy.